<DOC>
	<DOCNO>NCT00235989</DOCNO>
	<brief_summary>The purpose study determine high dose study drug effective preventing relapse patient Multiple Sclerosis .</brief_summary>
	<brief_title>Extension Prior Study Evaluating Safety Tolerability Two Doses BetaseronÂ® Treat Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Signed dated statement inform consent Completion Protocol 307000A Negative serum pregnancy test result Agreement adequate contraception , female patient Pregnancy lactation History alcohol drug abuse Inability administer subcutaneous injection either self caregiver Medical , psychiatric condition compromise patient 's ability give inform consent , understand patient information , comply study protocol , complete study Any significant change patient 's medical condition enrollment Study 307000A would lead his/her exclusion participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>interferon beta 1b</keyword>
	<keyword>Betaferon</keyword>
	<keyword>Betaseron</keyword>
</DOC>